Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RPL7L1 (ImmuneEditome ID:285855)

1. Gene summary of enriched editing regions for RPL7L1

Gene summary

Gene information	Gene symbol	RPL7L1
	Gene ID	285855
	GeneSynonyms	dJ475N16.4
	GeneCytomap	6p21.1
	GeneType	protein-coding
	GeneDescription	60S ribosomal protein L7-like 1\|large ribosomal subunit protein uL30-like 1
	GeneModificationdate	20230329
	UniprotID	A0A024RD36;Q6DKI1;A0A1W2PQ76
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr6:42881305-42883052:+	ENST00000497417.1	ENSG00000146223.13	RPL7L1	ncRNA_exonic	AluY,MER2B,AluSx,AluSz6,FRAM,AluSz	chr6:42881305-42883052:+.alignment
chr6:42886692-42889470:+	ENST00000397415.6	ENSG00000146223.13	RPL7L1	ncRNA_exonic	AluSp,AluSc,AluSz,Charlie4z	chr6:42886692-42889470:+.alignment
chr6:42886692-42889470:+	ENST00000459829.1	ENSG00000146223.13	RPL7L1	ncRNA_exonic	AluSp,AluSc,AluSz,Charlie4z	chr6:42886692-42889470:+.alignment
chr6:42886692-42889470:+	ENST00000483998.5	ENSG00000146223.13	RPL7L1	ncRNA_exonic	AluSp,AluSc,AluSz,Charlie4z	chr6:42886692-42889470:+.alignment

Top

2. Tumor-specific enriched editing regions for RPL7L1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr6:42886692-42889470:+	BRCA	EER	1.4510e-09
chr6:42886692-42889470:+	KIRC	EER	1.5998e-03
ENSG00000146223.13,RPL7L1	KIRC	EAG	5.2573e-04
chr6:42886692-42889470:+	LUAD	EER	4.6900e-04
ENSG00000146223.13,RPL7L1	LUAD	EAG	5.4514e-05
chr6:42886692-42889470:+	LUSC	EER	1.1653e-02
ENSG00000146223.13,RPL7L1	LUSC	EAG	3.3471e-03
ENSG00000146223.13,RPL7L1	THCA	EAG	1.4616e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000146223.13,RPL7L1	CESC	Cli	EAG	2.5972e-02	6.7248e-03	-0.2053
chr6:42886692-42889470:+	TGCT	Path	EER	4.5073e-03	1.4999e-03	0.3978
ENSG00000146223.13,RPL7L1	TGCT	Path	EAG	4.7370e-03	1.6170e-03	0.3953
ENSG00000146223.13,RPL7L1	UCS	Cli	EAG	1.5826e-02	4.9892e-02	-0.3674

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000146223.13,RPL7L1	LGG	EAG	3.8100e-03	1.5776e-02	1.5197e+10

Top

3. Enriched editing regions and immune related genes for RPL7L1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for RPL7L1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000146223.13,RPL7L1

ESCA

EAG

ENSG00000180104.11

chr5

462156:462307:464289:464412

0.3708

2.4235e-02

5.0707e-08

0.4421

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

EXOC3

T_cells_CD4_memory_activated

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000146223.13,RPL7L1

ESCA

EAG

ENSG00000081791.4

chr5

141934493:141934586:141937197:141937357

0.3564

3.5814e-02

2.2293e-07

0.4224

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_ADIPOGENESIS

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000142534.2

chr19

49497309:49497325:49497519:49497562:49497753:49498046:49499511:49499567

-0.2394

7.5800e-03

4.8559e-25

-0.5661

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000142534.2

chr19

49497193:49497325:49497519:49497562:49497944:49498046:49499511:49499688

-0.2394

7.5800e-03

4.8559e-25

-0.5661

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000142534.2

chr19

49497193:49497325:49497519:49497562:49497964:49498046:49499511:49499533

-0.2390

7.6942e-03

4.8559e-25

-0.5661

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000142534.2

chr19

49497193:49497325:49497519:49497562:49497987:49498046:49499511:49499569

-0.2390

7.7372e-03

4.9104e-25

-0.5660

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000142534.2

chr19

49497193:49497325:49497519:49497595:49497987:49498046:49499511:49499569

-0.2384

8.0256e-03

4.8074e-25

-0.5661

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399917:154400497:154400626:154400701:154400917

-0.2336

1.0076e-02

7.9297e-14

-0.4276

ACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400497:154400626:154400701:154400917

-0.2336

1.0076e-02

7.9297e-14

-0.4276

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000146223.13,RPL7L1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400497:154400626:154400701:154400811

-0.2336

1.0076e-02

7.9301e-14

-0.4276

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for RPL7L1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr6:42886692-42889470:+	ACC	EER	T_cells_regulatory_(Tregs)	1.5110e-02	0.3914
ENSG00000146223.13,RPL7L1	ACC	EAG	T_cells_regulatory_(Tregs)	1.5110e-02	0.3914
chr6:42886692-42889470:+	BLCA	EER	Macrophages_M1	3.0835e-04	0.2334
ENSG00000146223.13,RPL7L1	BLCA	EAG	T_cells_regulatory_(Tregs)	1.0616e-04	0.2481
chr6:42886692-42889470:+	BRCA	EER	T_cells_CD4_memory_resting	6.7992e-04	0.1251
ENSG00000146223.13,RPL7L1	BRCA	EAG	B_cells_naive	1.7985e-03	-0.1142
chr6:42886692-42889470:+	CHOL	EER	B_cells_memory	3.7728e-02	0.4356
ENSG00000146223.13,RPL7L1	CHOL	EAG	B_cells_memory	3.7458e-02	0.4362
chr6:42886692-42889470:+	COAD	EER	Dendritic_cells_activated	2.7732e-06	0.4665
ENSG00000146223.13,RPL7L1	COAD	EAG	Dendritic_cells_activated	3.3250e-06	0.4610
chr6:42881305-42883052:+	ESCA	EER	NK_cells_resting	3.9900e-03	0.4506
chr6:42886692-42889470:+	ESCA	EER	Macrophages_M1	2.1655e-02	0.1990
ENSG00000146223.13,RPL7L1	ESCA	EAG	NK_cells_resting	3.6037e-06	0.3814
ENSG00000146223.13,RPL7L1	GBM	EAG	B_cells_naive	1.3149e-03	0.3510
chr6:42886692-42889470:+	HNSC	EER	B_cells_naive	6.3022e-03	-0.1548
ENSG00000146223.13,RPL7L1	HNSC	EAG	B_cells_naive	6.7397e-03	-0.1536
chr6:42886692-42889470:+	KIRC	EER	Eosinophils	1.6322e-05	0.2567
ENSG00000146223.13,RPL7L1	KIRC	EAG	Plasma_cells	2.3978e-03	0.1811
ENSG00000146223.13,RPL7L1	KIRP	EAG	Dendritic_cells_resting	2.7456e-03	0.2722
ENSG00000146223.13,RPL7L1	LAML	EAG	NK_cells_activated	2.4256e-02	0.2837
ENSG00000146223.13,RPL7L1	LGG	EAG	Mast_cells_activated	4.8261e-03	0.2328
chr6:42886692-42889470:+	LIHC	EER	Mast_cells_resting	2.6681e-03	0.1608
ENSG00000146223.13,RPL7L1	LIHC	EAG	Mast_cells_resting	2.6681e-03	0.1608
chr6:42886692-42889470:+	LUAD	EER	Mast_cells_resting	5.3834e-04	-0.1763
ENSG00000146223.13,RPL7L1	LUAD	EAG	Dendritic_cells_resting	2.0984e-03	-0.1557
chr6:42886692-42889470:+	LUSC	EER	T_cells_follicular_helper	1.3901e-03	0.1915
ENSG00000146223.13,RPL7L1	LUSC	EAG	T_cells_follicular_helper	2.5270e-04	0.2171
ENSG00000146223.13,RPL7L1	MESO	EAG	Dendritic_cells_activated	2.6717e-03	0.3810
chr6:42881305-42883052:+	OV	EER	Dendritic_cells_resting	1.3443e-02	0.4082
chr6:42886692-42889470:+	OV	EER	Macrophages_M1	1.1426e-03	0.2026
ENSG00000146223.13,RPL7L1	OV	EAG	Mast_cells_activated	1.5166e-03	-0.1961
ENSG00000146223.13,RPL7L1	PAAD	EAG	T_cells_follicular_helper	6.9194e-03	0.2506
chr6:42886692-42889470:+	PCPG	EER	Plasma_cells	9.2843e-03	0.2291
ENSG00000146223.13,RPL7L1	PCPG	EAG	Plasma_cells	8.4680e-03	0.2309
chr6:42886692-42889470:+	PRAD	EER	T_cells_regulatory_(Tregs)	9.5617e-04	0.2462
ENSG00000146223.13,RPL7L1	PRAD	EAG	Eosinophils	3.1961e-02	0.1595
ENSG00000146223.13,RPL7L1	READ	EAG	NK_cells_resting	2.4771e-04	0.6396
chr6:42886692-42889470:+	SARC	EER	Dendritic_cells_activated	4.9861e-02	0.1588
ENSG00000146223.13,RPL7L1	SARC	EAG	Dendritic_cells_activated	4.9911e-02	0.1588
chr6:42886692-42889470:+	SKCM	EER	T_cells_CD8	1.9035e-02	0.1510
chr6:42886692-42889470:+	STAD	EER	Macrophages_M1	9.8332e-06	0.2466
ENSG00000146223.13,RPL7L1	STAD	EAG	Macrophages_M1	1.0266e-03	0.1819
chr6:42886692-42889470:+	TGCT	EER	NK_cells_activated	5.6529e-03	0.2658
ENSG00000146223.13,RPL7L1	TGCT	EAG	NK_cells_activated	2.0253e-03	0.2938
ENSG00000146223.13,RPL7L1	THCA	EAG	NK_cells_resting	3.5954e-02	0.1335
ENSG00000146223.13,RPL7L1	THYM	EAG	Macrophages_M1	3.0651e-04	0.4277
ENSG00000146223.13,RPL7L1	UCS	EAG	NK_cells_activated	2.9649e-02	-0.4042

Top

6. Enriched editing regions and immune gene sets for RPL7L1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr6:42886692-42889470:+	LUSC	EER	8.5214e-03		4.1727e-03	-0.1719
ENSG00000146223.13,RPL7L1	LUSC	EAG	5.5141e-03		2.8373e-04	-0.2153

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr6:42886692-42889470:+	CHOL	EER	2.0506e-02	-0.4798	2.5016e-02	-0.4660	1.1530e-02	-0.5170	3.6020e-02	-0.4392
ENSG00000146223.13,RPL7L1	CHOL	EAG	1.9649e-02	-0.4827	2.4392e-02	-0.4678	1.1527e-02	-0.5170	3.5356e-02	-0.4406
chr6:42886692-42889470:+	COAD	EER	2.9974e-04	-0.3686	1.7097e-02	-0.2481	2.6787e-04	-0.3714	3.4827e-02	-0.2203
ENSG00000146223.13,RPL7L1	COAD	EAG	2.2063e-04	-0.3741	4.2581e-02	-0.2108	4.4591e-04	-0.3569	1.7370e-02	-0.2462
ENSG00000146223.13,RPL7L1	KIRC	EAG	8.8978e-03	-0.1564	2.4300e-02	-0.1348	3.8779e-03	-0.1724	8.9738e-03	-0.1562

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000146223.13,RPL7L1	BLCA	GSVA_HALLMARK_APICAL_JUNCTION	EAG	1.3575e-02	-0.1595
ENSG00000146223.13,RPL7L1	BRCA	GSVA_HALLMARK_HEME_METABOLISM	EAG	3.3997e-04	-0.1309
chr6:42886692-42889470:+	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.3828e-06	0.1670
ENSG00000146223.13,RPL7L1	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	8.0859e-05	-0.2911
chr6:42886692-42889470:+	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.7177e-04	-0.2712
ENSG00000146223.13,RPL7L1	CHOL	GSVA_HALLMARK_HEME_METABOLISM	EAG	4.4126e-03	-0.5712
chr6:42886692-42889470:+	CHOL	GSVA_HALLMARK_HEME_METABOLISM	EER	4.5672e-03	-0.5694
chr6:42886692-42889470:+	COAD	GSVA_HALLMARK_UV_RESPONSE_UP	EER	5.4824e-05	-0.4077
ENSG00000146223.13,RPL7L1	COAD	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	2.2961e-05	-0.4239
ENSG00000146223.13,RPL7L1	ESCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.5194e-02	-0.2056
chr6:42886692-42889470:+	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.5619e-05	0.3650
ENSG00000146223.13,RPL7L1	GBM	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	3.5068e-03	-0.3208
ENSG00000146223.13,RPL7L1	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	5.0038e-04	0.1965
chr6:42886692-42889470:+	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.1509e-04	0.1961
chr6:42886692-42889470:+	KIRC	GSVA_HALLMARK_ANGIOGENESIS	EER	2.4119e-03	-0.1823
ENSG00000146223.13,RPL7L1	KIRC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	2.1117e-03	-0.1833
ENSG00000146223.13,RPL7L1	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.5519e-04	-0.3399
ENSG00000146223.13,RPL7L1	LAML	GSVA_HALLMARK_SPERMATOGENESIS	EAG	6.0780e-05	-0.4830
chr6:42886692-42889470:+	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.3347e-02	0.1327
ENSG00000146223.13,RPL7L1	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.3347e-02	0.1327
ENSG00000146223.13,RPL7L1	LUAD	GSVA_HALLMARK_HEME_METABOLISM	EAG	2.6398e-04	-0.1842
chr6:42886692-42889470:+	LUAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	2.6945e-04	-0.1854
chr6:42886692-42889470:+	LUSC	GSVA_HALLMARK_ANGIOGENESIS	EER	1.1839e-03	-0.1942
ENSG00000146223.13,RPL7L1	LUSC	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	9.0963e-05	-0.2317
chr6:42886692-42889470:+	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.9497e-07	0.3112
ENSG00000146223.13,RPL7L1	OV	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	9.6147e-03	-0.1606
chr6:42881305-42883052:+	OV	GSVA_HALLMARK_PEROXISOME	EER	1.9679e-02	0.3871
ENSG00000146223.13,RPL7L1	PAAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.9893e-02	-0.2169
chr6:42886692-42889470:+	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.0180e-02	-0.2052
ENSG00000146223.13,RPL7L1	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.6436e-02	-0.2109
ENSG00000146223.13,RPL7L1	PRAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.2291e-05	-0.3187
chr6:42886692-42889470:+	PRAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	5.6815e-05	-0.2978
ENSG00000146223.13,RPL7L1	READ	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	4.9574e-02	-0.3745
chr6:42886692-42889470:+	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.6193e-02	0.1695
ENSG00000146223.13,RPL7L1	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.6694e-02	0.1691
chr6:42886692-42889470:+	SKCM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.9138e-03	-0.1806
ENSG00000146223.13,RPL7L1	SKCM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.2405e-03	-0.2039
chr6:42886692-42889470:+	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.2724e-06	0.2538
ENSG00000146223.13,RPL7L1	STAD	GSVA_HALLMARK_PEROXISOME	EAG	6.7732e-03	-0.1504
chr6:42886692-42889470:+	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.5362e-02	-0.2037
ENSG00000146223.13,RPL7L1	THCA	GSVA_HALLMARK_ADIPOGENESIS	EAG	3.6042e-02	-0.1335
ENSG00000146223.13,RPL7L1	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.0207e-05	-0.4796
chr6:42886692-42889470:+	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.3254e-03	-0.3167
ENSG00000146223.13,RPL7L1	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.4860e-03	-0.3136
ENSG00000146223.13,RPL7L1	UCS	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	3.1427e-03	0.5294
ENSG00000146223.13,RPL7L1	UVM	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.9796e-02	-0.4378

Top

7. Enriched editing regions and drugs for RPL7L1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000146223.13,RPL7L1	ACC	GW.441756	EAG	6.3123e-03	-0.4352
chr6:42886692-42889470:+	ACC	GW.441756	EER	6.3123e-03	-0.4352
chr6:42886692-42889470:+	BLCA	Metformin	EER	1.1352e-02	-0.1649
ENSG00000146223.13,RPL7L1	BLCA	CGP.082996	EAG	4.2829e-03	0.1842
chr6:42886692-42889470:+	BRCA	ABT.888	EER	1.4505e-03	-0.1174
ENSG00000146223.13,RPL7L1	BRCA	ABT.263	EAG	5.6204e-03	-0.1014
ENSG00000146223.13,RPL7L1	CESC	Embelin	EAG	1.1727e-02	0.1885
chr6:42886692-42889470:+	CESC	FH535	EER	3.0165e-03	0.2224
ENSG00000146223.13,RPL7L1	CHOL	JNK.Inhibitor.VIII	EAG	4.9633e-02	0.4138
chr6:42886692-42889470:+	COAD	CCT007093	EER	1.1386e-04	-0.3915
ENSG00000146223.13,RPL7L1	COAD	AZ628	EAG	3.1377e-05	0.4175
chr6:42886692-42889470:+	ESCA	CGP.60474	EER	1.6266e-02	-0.2080
chr6:42881305-42883052:+	ESCA	AZD.2281	EER	2.0055e-03	-0.4796
ENSG00000146223.13,RPL7L1	GBM	Lenalidomide	EAG	6.0818e-04	-0.3728
ENSG00000146223.13,RPL7L1	HNSC	FH535	EAG	9.5754e-04	0.1867
chr6:42886692-42889470:+	HNSC	FH535	EER	9.8148e-04	0.1863
ENSG00000146223.13,RPL7L1	KIRC	AZD6244	EAG	2.9363e-10	-0.3658
chr6:42886692-42889470:+	KIRC	AS601245	EER	3.1595e-07	0.3025
ENSG00000146223.13,RPL7L1	KIRP	Elesclomol	EAG	1.2701e-02	0.2278
ENSG00000146223.13,RPL7L1	LAML	LFM.A13	EAG	1.5319e-02	-0.3043
chr6:42886692-42889470:+	LIHC	Bleomycin	EER	2.0114e-05	0.2287
ENSG00000146223.13,RPL7L1	LIHC	Bleomycin	EAG	2.0114e-05	0.2287
ENSG00000146223.13,RPL7L1	LUAD	Bexarotene	EAG	9.6697e-03	0.1312
chr6:42886692-42889470:+	LUAD	CMK	EER	6.3134e-04	-0.1741
chr6:42886692-42889470:+	LUSC	ABT.888	EER	5.3029e-04	-0.2072
ENSG00000146223.13,RPL7L1	LUSC	ABT.888	EAG	5.4913e-05	-0.2386
ENSG00000146223.13,RPL7L1	MESO	A.770041	EAG	4.9329e-02	-0.2549
chr6:42886692-42889470:+	OV	Bexarotene	EER	2.5088e-05	0.2606
ENSG00000146223.13,RPL7L1	OV	GSK269962A	EAG	8.9668e-03	0.1621
chr6:42881305-42883052:+	OV	ABT.263	EER	5.6029e-03	-0.4524
ENSG00000146223.13,RPL7L1	PAAD	A.770041	EAG	1.0004e-03	-0.3068
chr6:42886692-42889470:+	PCPG	AZD.2281	EER	1.5978e-03	-0.2762
ENSG00000146223.13,RPL7L1	PCPG	AZD.2281	EAG	1.4019e-03	-0.2784
chr6:42886692-42889470:+	PRAD	ABT.888	EER	1.6758e-07	-0.3820
ENSG00000146223.13,RPL7L1	PRAD	Erlotinib	EAG	5.0490e-05	-0.2965
ENSG00000146223.13,RPL7L1	READ	A.770041	EAG	5.3645e-04	-0.6217
ENSG00000146223.13,RPL7L1	SARC	Cisplatin	EAG	3.1837e-03	-0.2370
chr6:42886692-42889470:+	SARC	Cisplatin	EER	3.1768e-03	-0.2370
chr6:42886692-42889470:+	SKCM	CGP.082996	EER	5.7913e-05	-0.2560
ENSG00000146223.13,RPL7L1	SKCM	BIBW2992	EAG	8.9519e-03	-0.1657
ENSG00000146223.13,RPL7L1	STAD	JNK.Inhibitor.VIII	EAG	4.9579e-04	-0.1927
chr6:42886692-42889470:+	STAD	Cisplatin	EER	3.9539e-04	-0.1987
chr6:42881305-42883052:+	STAD	GDC0941	EER	4.1300e-02	-0.2558
ENSG00000146223.13,RPL7L1	TGCT	CEP.701	EAG	5.6082e-03	-0.2648
chr6:42886692-42889470:+	TGCT	CEP.701	EER	2.4584e-03	-0.2899
ENSG00000146223.13,RPL7L1	THCA	AZD.2281	EAG	8.8435e-03	-0.1669
ENSG00000146223.13,RPL7L1	THYM	Embelin	EAG	2.7475e-10	0.6788
ENSG00000146223.13,RPL7L1	UCEC	FH535	EAG	1.5143e-02	0.2423
chr6:42886692-42889470:+	UCEC	FH535	EER	1.3902e-02	0.2453
ENSG00000146223.13,RPL7L1	UCS	AZD7762	EAG	1.4333e-02	-0.4499

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType